Raymond James & Associates Raises Stock Position in UiPath Inc. (NYSE:PATH)

Raymond James & Associates boosted its stake in UiPath Inc. (NYSE:PATH) by 40.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 230,331 shares of the healthcare company’s stock after purchasing an additional 66,114 shares during the period. Raymond James & Associates’ holdings in UiPath were worth $2,921,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PATH. Mark Sheptoff Financial Planning LLC purchased a new position in shares of UiPath during the 4th quarter worth $25,000. ORG Partners LLC lifted its position in UiPath by 875.6% during the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares in the last quarter. GAMMA Investing LLC bought a new stake in UiPath during the fourth quarter valued at about $36,000. Lindbrook Capital LLC increased its position in UiPath by 46.0% in the first quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after buying an additional 639 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its stake in shares of UiPath by 122.5% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,556 shares of the healthcare company’s stock worth $58,000 after buying an additional 1,407 shares during the period. 62.50% of the stock is currently owned by hedge funds and other institutional investors.

UiPath Price Performance

UiPath stock opened at $12.88 on Monday. UiPath Inc. has a 1-year low of $10.37 and a 1-year high of $27.87. The firm has a market capitalization of $7.38 billion, a P/E ratio of -80.50 and a beta of 0.86. The company’s 50-day moving average is $12.18 and its 200 day moving average is $17.04.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PATH shares. BMO Capital Markets reduced their price objective on shares of UiPath from $28.00 to $14.00 and set a “market perform” rating for the company in a research note on Monday, June 3rd. Wells Fargo & Company dropped their target price on shares of UiPath from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Friday, June 21st. TD Cowen reiterated a “hold” rating and issued a $17.00 price target (down previously from $28.00) on shares of UiPath in a research note on Thursday, May 30th. DA Davidson cut their price objective on UiPath from $24.00 to $13.00 and set a “neutral” rating for the company in a research report on Thursday, May 30th. Finally, Mizuho decreased their target price on UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.94.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.